BDX logo

BDX

Becton Dickinson and Company

$154.51
$0.00(0.00%)
51
Overall
95
Value
16
Tech
44
Quality
How is this score calculated?
Market Cap
$53.26B
Volume
2.37M
52W Range
$153.18 - $213.08
Target Price
$190.18

Company Overview

Mkt Cap$53.26BPrice$154.51
Volume2.37MChange+0.00%
P/E Ratio31.7Open$154.56
Revenue$21.8BPrev Close$154.51
Net Income$1.7B52W Range$153.18 - $213.08
Div Yield4.20%Target$190.18
Overall51Value95
Quality44Technical16

No chart data available

About Becton Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Sector: Healthcare
Industry: Medical Instruments & Supplies

Latest News

3 Best Dividend Aristocrat Stocks to Buy Now, 04/02/2026

Dividend aristocrats are S&P 500 companies that have raised their shareholder payouts every year for at least 25 years. The article uses the TipRan...

Solomon Oladipupo3 days ago

BCAL seeks Medicare backing for Avantect pancreatic cancer blood test

TipRanks Australian Auto-Generated Newsdesk6 days ago

Abingdon Health Wins £4.8m U.S. Contracts for Multiplex Lateral Flow Systems

TipRanks UK Auto-Generated Newsdesk7 days ago

BCAL speeds national rollout of Avantect cancer blood tests

TipRanks Australian Auto-Generated Newsdesk11 days ago

BCAL speeds national rollout of Avantect cancer blood tests

TipRanks Australian Auto-Generated Newsdesk11 days ago
ABCD
1SymbolPriceChangeVol
2BDX$154.510%2.37M
3
4
5
6

Get Becton Dickinson and Company Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.